Kim Jeong-Han, Yoo Shin Hye, Keam Bhumsuk, Heo Dae Seog
Division of Infectious Diseases, Department of Internal Medicine, Ewha Woman University College of Medicine, Seoul Hospital, Seoul, Republic of Korea.
Center for Palliative Care and Clinical Ethics, Seoul National University Hospital, Seoul, Republic of Korea.
J Antimicrob Chemother. 2022 Dec 23;78(1):302-308. doi: 10.1093/jac/dkac405.
A substantial number of hospitalized patients with terminal cancer at the end-of-life phase receive antibiotics, even with imminent death. We evaluated the impact of palliative care consultation on antibiotic use in hospitalized patients with terminal cancer during the end-of-life phase.
We identified adult patients with metastatic solid cancer who died at a tertiary medical centre in Seoul, Republic of Korea, following at least 4 days of hospitalization (January 2018-December 2020). Patients were divided into palliative and non-palliative care consultation groups. Propensity score-weighted, multivariable logistic regression analysis was used to compare the proportion of patients receiving antibiotics within 3 days before death between the two groups.
Among 1143 patients analysed, 940 (82.2%) received antibiotics within 3 days before death. The proportion of patients receiving antibiotics was significantly lower (propensity score-weighted P < 0.001) in the palliative care consultation group (344/468; 73.5%) than in the non-palliative care consultation group (596/675; 88.3%). The decrease in the proportion of patients receiving antibiotics in the palliative care consultation group was significant for a carbapenem (42.4% versus 22.4%; P < 0.001), a glycopeptide (23.3% versus 11.1%; P < 0.001) and a quinolone (30.5% versus 19.4%; P = 0.012). In the multivariable logistic regression analysis, receiving palliative care consultation (adjusted OR 0.46, 95% CI 0.33-0.65; P < 0.001) was independently associated with reduced antibiotic use during the end-of-life phase.
Palliative care consultation may reduce aggressive antibiotic use in hospitalized patients with terminal cancer during the end-of-life phase.
相当一部分处于临终阶段的晚期癌症住院患者即便濒临死亡仍接受抗生素治疗。我们评估了姑息治疗会诊对处于临终阶段的晚期癌症住院患者抗生素使用情况的影响。
我们确定了在韩国首尔一家三级医疗中心住院至少4天(2018年1月至2020年12月)后死亡的成年转移性实体癌患者。患者被分为姑息治疗会诊组和非姑息治疗会诊组。采用倾向评分加权多变量逻辑回归分析比较两组患者在死亡前3天内接受抗生素治疗的比例。
在分析的1143例患者中,940例(82.2%)在死亡前3天内接受了抗生素治疗。姑息治疗会诊组患者接受抗生素治疗的比例(344/468;73.5%)显著低于非姑息治疗会诊组(596/675;88.3%)(倾向评分加权P<0.001)。姑息治疗会诊组中接受碳青霉烯类抗生素治疗的患者比例下降显著(42.4%对22.4%;P<0.001),糖肽类抗生素(23.3%对11.1%;P<0.001)和喹诺酮类抗生素(30.5%对19.4%;P=0.012)。在多变量逻辑回归分析中,接受姑息治疗会诊(调整后的比值比为0.46,95%置信区间为0.33 - 0.65;P<0.001)与临终阶段抗生素使用减少独立相关。
姑息治疗会诊可能会减少处于临终阶段的晚期癌症住院患者对抗生素的过度使用。